Abstract
Overview:
Kick off 2026 with a new AD/PD™ Research Spotlight Session highlighting emerging evidence from early-phase clinical trials investigating stem cell–derived dopaminergic neuron transplantation for Parkinson’s disease.
Guided by Dr. Roger A. Barker, leading experts, Dr. Claire Henchcliffe and Dr Fasano Alfonso, discussed the scientific rationale for restoring the nigrostriatal pathway, review key findings from ongoing and completed studies, and address the methodological and translational challenges of regenerative medicine.
Objectives:
By the end of this webinar, participants will be able to:
- Explain the rationale for targeting the nigrostriatal dopaminergic pathway using regenerative therapies.
- Summarize current data from clinical trials involving dopamine cell–based interventions.
- Describe early-phase clinical trial approaches for stem cell–derived transplant therapies in Parkinson’s disease.
- Recognize challenges in clinical trial design, interpretation, and future research directions.
Access Record
Visit Resource